Silybin - Vitamin E- Phospholipids Complex Reduces Liver Fibrosis in Patients With Chronic Hepatitis C Treated With Peg-IFN-a and RBV

Chronic hepatitis C is both a virologic and a fibrotic disease, with mortality resulting mainly from the complications of cirrhosis and HCC.

The investigators' aim will be to evaluate the impact on of supplementation with a new pharmaceutical complex of silybin-vitamin E-phospholipids in patients with chronic hepatitis C treated with Pegylated-Interferon-α2b plus Ribavirin.

Inclusion Criteria:

• 18 years of age or older,
• infection by HCV
• under treatment with pegylated interferon 2 alpha and ribavirin

Exclusion Criteria:

• other liver diseases
• cancer
• severe jaundice
• pulmonary and renal chronic diseases
• prostatic diseases
• autoimmune diseases
• diabetes mellitus